Allogeneic Anti-CD19/BCMA CAR-T for Refractory Graves' Disease

Clinical trial NCT07261345 · RECRUITING

Trial details

NCT number: NCT07261345
Sponsor: Shanghai Zhongshan Hospital
Status: RECRUITING
Phase: Early Phase 1
Study type: INTERVENTIONAL

Graves' Disease

Start date: 2025-12-19
Primary completion: 2027-12-01
Enrollment: 4

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.